BufferGel

BufferGel is a microbicide developed to prevent the transmission of sexually transmitted infections. It is a gel that is applied topically to the vagina or rectum before sexual intercourse. BufferGel works by maintaining the natural acidity of the vagina, which is typically disrupted during intercourse, allowing pathogens to thrive.

Mechanism of Action

BufferGel is a weakly acidic hydrogel that is designed to protect against infection by maintaining the natural acidity of the vagina during sexual intercourse. The gel contains polyacrylic acid, which buffers the pH of the vagina to its normal level of around 4.5. This acidic environment is inhospitable to many pathogens, including HIV, herpes simplex virus, and human papillomavirus.

Clinical Trials

BufferGel has been tested in several clinical trials. In a Phase II/IIb trial, BufferGel was found to be safe and well-tolerated, but did not significantly reduce the risk of HIV infection compared to a placebo. A subsequent Phase III trial, the HPTN 035 trial, also found that BufferGel did not significantly reduce the risk of HIV infection.

Side Effects

The most common side effects of BufferGel are mild and include vaginal irritation and discomfort during intercourse. In clinical trials, these side effects were generally mild and did not lead to discontinuation of the gel.

See Also

• Microbicide
• Sexually transmitted infections
• HIV
• Herpes simplex virus
• Human papillomavirus

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!